Immunocore Holdings plc
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-97.9% vs price
Base Case (Median)
-96.0% vs price
Bull Case (75th pct.)
-94.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.75 | -92.2% | High (40%) |
| EV/EBITDA | $0.08 | -99.8% | Medium (20%) |
Based on 2 out of 8 methods, IMCR appears overvalued at the current price of $35.05. The base case fair value of $1.41 implies 96.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.